Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
出版年份 2020 全文链接
标题
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
作者
关键词
-
出版物
ANNALS OF NEUROLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2020-06-16
DOI
10.1002/ana.25811
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Method comparison study of the Elecsys® β-Amyloid (1–42) CSF assay versus comparator assays and LC-MS/MS
- (2019) Leslie M. Shaw et al. CLINICAL BIOCHEMISTRY
- Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers
- (2019) Tessandra Stewart et al. JOURNAL OF ALZHEIMERS DISEASE
- Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease
- (2018) Min Shi et al. Alzheimers & Dementia
- CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
- (2018) Oskar Hansson et al. Alzheimers & Dementia
- CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders
- (2018) David J. Irwin et al. NEUROLOGY
- Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease
- (2018) Marthe Gurine Førland et al. PARKINSONISM & RELATED DISORDERS
- Parkinson’s disease: evolution of cognitive impairment and CSF Aβ1–42 profiles in a prospective longitudinal study
- (2018) Stefanie Lerche et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders
- (2018) David G. Coughlin et al. ANNALS OF NEUROLOGY
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
- (2018) Kenneth Marek et al. Annals of Clinical and Translational Neurology
- Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study
- (2017) Anette Schrag et al. LANCET NEUROLOGY
- Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis
- (2017) David J Irwin et al. LANCET NEUROLOGY
- Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
- (2017) Brit Mollenhauer et al. NEUROLOGY
- Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
- (2017) Chelsea Caspell-Garcia et al. PLoS One
- CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study
- (2016) Ju-Hee Kang et al. ACTA NEUROPATHOLOGICA
- Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid
- (2016) Tobias Bittner et al. Alzheimers & Dementia
- Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson’s Disease1
- (2016) Mariateresa Buongiorno et al. JOURNAL OF ALZHEIMERS DISEASE
- Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
- (2016) Sara Hall et al. MOVEMENT DISORDERS
- A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
- (2016) Clifford R. Jack et al. NEUROLOGY
- Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies
- (2016) Guerry M. Peavy et al. PARKINSONISM & RELATED DISORDERS
- CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease
- (2015) Mark Terrelonge et al. JOURNAL OF MOLECULAR NEUROSCIENCE
- Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
- (2015) Daniel Weintraub et al. MOVEMENT DISORDERS
- Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study
- (2015) Kathrin Brockmann et al. PARKINSONISM & RELATED DISORDERS
- CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease
- (2015) Changqin Liu et al. PARKINSONISM & RELATED DISORDERS
- Alzheimer’s disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology
- (2015) Alan Rembach et al. Alzheimers Research & Therapy
- Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort
- (2014) Tessandra Stewart et al. AMERICAN JOURNAL OF PATHOLOGY
- CSF A 42 predicts early-onset dementia in Parkinson disease
- (2014) G. Alves et al. NEUROLOGY
- CSF biomarkers and clinical progression of Parkinson disease
- (2014) S. Hall et al. NEUROLOGY
- Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease
- (2013) Jing Zhang et al. ACTA NEUROPATHOLOGICA
- Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
- (2013) Jon B. Toledo et al. ACTA NEUROPATHOLOGICA
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
- (2013) Clifford R Jack et al. LANCET NEUROLOGY
- Neuropathologic substrates of Parkinson disease dementia
- (2012) David J. Irwin et al. ANNALS OF NEUROLOGY
- Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders
- (2012) Sara Hall et al. ARCHIVES OF NEUROLOGY
- An evaluation of the impact ofMAPT,SNCAandAPOEon the burden of Alzheimer's and Lewy body pathology
- (2012) Christian Wider et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Cerebrospinal fluid amyloid- and phenotypic heterogeneity in de novo Parkinson's disease
- (2012) G. Alves et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
- (2012) Irene Litvan et al. MOVEMENT DISORDERS
- APOE ϵ4 Increases Risk for Dementia in Pure Synucleinopathies
- (2012) Debby Tsuang et al. JAMA Neurology
- Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
- (2011) Leslie M. Shaw et al. ACTA NEUROPATHOLOGICA
- The Parkinson Progression Marker Initiative (PPMI)
- (2011) Kenneth Marek et al. PROGRESS IN NEUROBIOLOGY
- CSF amyloid- and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study
- (2010) G. Alves et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- CSF Aβ42and tau in Parkinson's disease with cognitive impairment
- (2010) Thomas J. Montine et al. MOVEMENT DISORDERS
- CSF amyloid 1-42 predicts cognitive decline in Parkinson disease
- (2010) A. Siderowf et al. NEUROLOGY
- A clinico-pathological study of subtypes in Parkinson's disease
- (2009) M. Selikhova et al. BRAIN
- Cerebrospinal fluid tau and ptau181increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
- (2009) Anne M. Fagan et al. EMBO Molecular Medicine
- Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease
- (2009) Yaroslau Compta et al. MOVEMENT DISORDERS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started